

CME QUESTIONS

Clinical Update on Oncology Treatments and Trends**Continuing Medical Education Accreditation**

The University of Cincinnati College of Medicine designates this educational activity for a maximum of 2.5 *AMA PRA Category 1 credits*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Cincinnati College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor medical education for physicians.

Instructions

After reading "Clinical Update on Oncology Treatments and Trends," complete the program evaluation and select the 1 best answer to each of the following questions. A statement of continuing education hours will be mailed to those who successfully complete (with a minimum score of 70%) the examination at the conclusion of the program.

1. For what clinical indication has the US Food and Drug Administration (FDA) approved the use of erlotinib?

- a) With combination chemotherapy for unresectable non-small-cell lung cancer (NSCLC).
- b) With combination chemotherapy for colorectal cancer.
- c) As a single agent for the first-line treatment of NSCLC.
- d) As a single agent for locally advanced or metastatic NSCLC.

2. A study begun at Vanderbilt University in 2001 found highly favorable results in the treatment of advanced untreated or metastatic NSCLC with a regimen consisting of:

- a) Gefitinib, paclitaxel, and carboplatin.
- b) Bevacizumab, docetaxel, and cisplatin.
- c) Bevacizumab, paclitaxel, and oxaliplatin.
- d) Bevacizumab, paclitaxel, and carboplatin.

3. What proportion of lung cancers have metastasized by the time they are detected?

- a) 50%
- b) 60%
- c) 75%
- d) 90%

4. The survival rate found with the use of spiral computed tomography in screening for lung cancer in the International Early Lung Cancer Project has been better than:

- a) 85%
- b) 65%
- c) 95%
- d) 50%

5. An issue of debate in adjuvant therapy for colorectal cancer has been:

- a) Whether it benefits patients with stage IIIB disease as much as those with stage IIIA disease.
- b) Whether it benefits patients with stage III disease as much as those with stage II disease.
- c) Whether it is applicable to patients with locoregional disease.
- d) Whether it is applicable to patients who have undergone adjunctive radiotherapy.

6. Phase 2 and 3 clinical studies have clearly shown that adding which of the following drugs to a first-line regimen of 5-fluorouracil (5-FU) and leucovorin (LV) for advanced colorectal cancer improves survival over that with 5-FU and LV alone?

- a) Erlotinib
- b) Cyclophosphamide
- c) Bevacizumab
- d) Docetaxel

7. Which of the following laboratory techniques are used in determining human epidermal growth factor receptor 2 over-expressing breast carcinomas for treatment with trastuzumab?

- a) Radioimmunoassay
- b) Enzyme immunoassay
- c) Fluorescence in situ hybridization
- d) Western blotting

8. The combined data from National Surgical Adjuvant Breast and Bowel Project trial B-31 and North Central Treatment Group trial N9831 found that adding trastuzumab to chemotherapy in the adjuvant treatment of breast cancer produced an absolute gain of which of the following percentages in disease-free survival at 3 years?

- a) 25%
- b) 12%
- c) 33%
- d) 42%

9. The type of non-Hodgkin's lymphoma that has shown the most significant increase in older persons is:

- a) Mixed large- and small-B-cell lymphoma
- b) Follicular lymphoma
- c) Diffuse large-B-cell lymphoma
- d) T-cell lymphoma

10. For nearly a quarter century the gold standard for treating diffuse large-cell lymphoma was a combination of drugs known as CHOP, named for the Children's Hospital of Philadelphia, where the regimen was developed. The combination of drugs includes:

- a) Cyclophosphamide, doxorubicin, vincristine, and prednisone
- b) Rituximab, vincristine, and prednisone
- c) Methotrexate, cytarabine, doxorubicin, dexamethasone
- d) Anthracyclines vincristine, prednisone

CME EVALUATION

CME TEST FORM

Clinical Update on Oncology
Treatments and Trends

Please circle your answers:

1. a b c d
2. a b c d
3. a b c d
4. a b c d
5. a b c d
6. a b c d
7. a b c d
8. a b c d
9. a b c d
10. a b c d

(PLEASE PRINT CLEARLY)

Name/Degree _____

Street _____

City _____

State/ZIP _____

Daytime Phone _____

Fax _____

E-mail _____

Sponsored by the University of Cincinnati for
2.5 AMA PRA Category 1 credits™.

Release Date: March 31, 2006

Expiration Date: March 31, 2007

Answer Form Instructions: Testing and Grading Procedures

1. Each participant achieving a passing grade of 70% or higher on any examination will receive an official computer form stating the number of CME credits earned. This form should be safeguarded and may be used as documentation of credits earned.
2. Participants receiving a failing grade on any exam will be notified and permitted to take 1 reexamination at no cost.
3. All answers should be circled on the answer form.
4. To receive credit certification electronically, please provide your e-mail address. Detach and mail or fax this page to: University of Cincinnati, Office of CME, PO Box 670567, Cincinnati, OH 45267-0567; phone: 513-558-7277; fax: 513-558-1708. Please print clearly to ensure receipt of CME credit.

CME Activity Evaluation

Activity Evaluation

How long did it take you to complete this activity?
_____ minutes

How well did this activity achieve its educational objectives?
 Very well Well Somewhat Not at all

What overall grade would you assign this activity?
 A B C D

Did this activity exhibit promotional bias for any pharmaceutical agents?
 Yes No

Will you make changes in your practice as a result of the information presented in this lesson?
 Yes No

Proj A144

*Clinical Update on
Oncology Treatments and Trends*

GOAL

To provide participants with a clinical update on treatments for lung, colorectal, and breast cancers, and lymphoproliferative disorders.

TARGET AUDIENCE

This activity is intended for primary care physicians, oncologists, medical directors, and other managed care decision makers.

LEARNING OBJECTIVES

After participating in this activity, participants should be better able to:

- Explain the new developments associated with treating some forms of cancer with monoclonal antibodies.
- Describe some of the recent techniques used to detect cancer at an early stage.
- Discuss how adjuvant chemotherapeutic regimens are being used to treat breast and other forms of cancer.

CONTINUING MEDICAL EDUCATION ACCREDITATION

The University of Cincinnati College of Medicine designates this educational activity for a maximum of 2.5 *AMA PRA Category 1 credits*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Cincinnati College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor medical education for physicians.

Release Date: **March 31, 2006**. Expiration Date: **March 31, 2007**.

FUNDING

This program is supported by an educational grant from **Genentech**.



The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.